sponsored
PatientsVille.com Logo

PatientsVille

Rifampin Medical Research Studies

Up-to-date List of Rifampin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Rifampin Medical Research Studies

Rank Status Study
1 Unknown  An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
Conditions: HIV Infection;   Tuberculosis
Intervention: Drug: Rifampin
Outcome Measures: Plasma levels of Rifampin and lopinavir-ritonavir (pharmacokinetics).;   HIV response to treatment;   Adverse events
2 Recruiting Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
Conditions: Drug Interactions;   Pharmacokinetics
Interventions: Drug: Daptomycin;   Drug: Rifampin
Outcome Measures: Daptomycin total, renal, and non-renal clearance;   Daptomycin Volume of Distribution;   Daptomycin Elimination Rate Constant;   Daptomycin Free and Total Peak Concentrations;   Daptomycin Free and Total 24 hour Concentrations;   Daptomycin Free and Total Area Under the Concentration-Time Curve (AUC) from 0 to 24 hours;   Daptomycin Free and Total AUC from 0 to Infinity;   Percent Protein Binding of Daptomycin;   P-glycoprotein Polymorphism;   Number of Participants with Adverse Events
3 Not yet recruiting The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin
Condition: Healthy
Interventions: Drug: Rosuvastatin;   Drug: Rosuvastatin plus Rifampin
Outcome Measures: Area-under-the-concentration curve (AUC) of rosuvastatin;   Maximum plasma concentration (Cmax) of rosuvastatin;   Time to concentration maximum (Tmax) of rosuvastatin
4 Recruiting A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
Condition: Cancer
Interventions: Drug: Dabrafenib 150 mg twice a day (BID);   Drug: Rabeprazole 40 mg once daily (OD);   Drug: Rifampin 600 mg OD
Outcome Measures: PK assessment (Cmax) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment (tmax) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment (AUC[0-tau]) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment of Dabrafenib co administered with rabeprazole or Rifampin;   PK assessment (AUC[0-tau]) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   PK assessment (Cmax and Ctau,) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   PK assessment (tmax) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   Ratio of metabolite to Dabrafenib;   Safety and tolerability assessment to measure vital signs;   Safety and tolerability assessment for 12-lead ECG;   Safety and tolerability assessment for laboratory tests;   Safety and tolerability assessment of dabrafenib in combination with rabeprazole or Rifampin;   Concentrations of Rabeprazole in the presence of Dabrafenib;   Concentrations of Rifampin in the presence of Dabrafenib
5 Recruiting Trial of High-Dose Rifampin in Patients With TB
Condition: Tuberculosis
Intervention: Drug: Higher-Dose Rifampin
Outcome Measures: Difference in steady state pharmacokinetic exposure of RIF and 25-desacetyl-Rifampin.;   Difference in sputum culture sterilization during the initial 8 weeks.;   Incidence of adverse events during the initial 8 weeks of daily four-drug treatment.
6 Not yet recruiting Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
Conditions: AIDS;   Tuberculosis
Intervention: Drug: Lopinavir/ritonavir and ritonavir
Outcome Measures: Proportion of patients with expected Cmax of Rifampin.;   Proportion of patients with expected pre dose concentration of lopinavir.;   Proportion of patients with successful treatment of HIV therapy.;   Proportion of patients with expected AUC of Rifampin;   Proportion of patient with success of tuberculosis therapy;   Proportion of patients with expected Cmax and AUC of lopinavir
7 Unknown  Controlled Trial: 5-Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus
Condition: Scrub Typhus
Interventions: Drug: doxycycline;   Drug: Rifampin
Outcome Measures: The primary end point was the fever clearance time;   The secondary end point was evaluated according to the following definitions. "Cure ", "Failure", "Relapse"
8 Unknown  A Pilot Study of Inflammatory Markers in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: doxycycline;   Drug: Rifampin;   Drug: placebo
Outcome Measures: IL-1beta;   TNF-alpha;   MCP-1;   IL-4;   IL-10;   Other inflammatory markers.
9 Unknown  Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii
Condition: Drug Safety
Interventions: Drug: Colistin;   Drug: Colistin plus Rifampicin
Outcome Measures: number of subjects with cure or improvement;   number of subjects with eradication of causative bacteria
10 Recruiting A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib;   Drug: Rifampin
Outcome Measures: Pharmacokinetics: Area under the concentration time curve;   Pharmacokinetics: Maximum plasma concentration;   Pharmacokinetics: Time to maximum plasma concentration;   Pharmacokinetics: Terminal half-life;   Pharmacokinetics: Apparent clearance;   Safety: Incidence of adverse events
11 Recruiting Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
Condition: Hip Prosthetic Joint Infection
Interventions: Drug: VANCOMYCIN;   Drug: CEFTRIAXONE;   Drug: CLINDAMYCIN;   Drug: SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE);   Drug: FLUOROQUINOLONE;   Drug: LINEZOLID;   Drug: Rifampin
Outcome Measures: Clinical cure rate;   Cure rate
12 Recruiting Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Conditions: Solid Tumors;   Lymphoma
Interventions: Drug: alisertib;   Drug: esomeprazole;   Drug: Rifampin
Outcome Measures: alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of esomeprazole;   alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of Rifampin;   Change in QTc following single and multiple dose administration of alisertib;   alisertib steady-state PK parameters (AUC and Cmax);   Number of adverse events;   Changes in ECG intervals following single and multiple dose administration of alisertib
13 Recruiting Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine
Condition: Healthy
Interventions: Drug: Placebo;   Drug: Rifampicin;   Drug: Buprenorphine
Outcome Measures: Concentration of buprenorphine and its metabolites in plasma and urine concebtration of buprenorphine;   Pharmacodynamic effects;   Analgesia
14 Recruiting Phase 1 Pharmacokinetics Study of Oral IXAZOMIB in Patients With Advanced Nonhematologic Malignancies or Lymphoma
Conditions: Nonhematologic Malignancies;   Lymphoma
Interventions: Drug: IXAZOMIB Capsule B formulation;   Drug: IXAZOMIB Capsule A formulation;   Drug: ketoconazole;   Drug: Rifampin
Outcome Measures: Arm 1: Ratio of geometric mean Cmax and AUC0-tlast of IXAZOMIB administered as Capsule B formulation with ketoconazole versus when administered as a single agent and 90% confidence intervals (CI);   Arm 2: Ratio of geometric mean Cmax and AUC0-tlast of Capsule B formulation versus Capsule A formulation and 90% CI;   Arm 3: Capsule B formulation ratio of geometric mean Cmax and AUC0-tlast of IXAZOMIB administered as Capsule B formulation with food versus without food and 90% CI;   Arm 4: Ratio of geometric mean Cmax and AUC0-tlast of IXAZOMIB administered as Capsule B with Rifampin versus when administered as a single agent and 90% confidence intervals (CI);   Adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements;   Measures of disease response according to standard criteria
15 Recruiting Rifampin and Efavirenz Interactions in Older Children
Conditions: HIV;   Tuberculosis
Intervention:
Outcome Measures: Area under time curve from time 0-24 hours(AUC0-24h) of efavirenz;   Number of children with grade 3 or 4 liver enzymes elevations compared to baseline, new onset of skin rash, nausea, vomiting or treatment modification due to drug side effects;   Number of children with efavirenz 24-hour post-dose concentration (C24h) < 1000 ng/mL;   Number of children who discontinue efavirenz therapy due to drug side effects;   Trough concentration (C24h) of efavirenz;   AUC, Cmax and clearance of efavirenz on and off Rifampin-containing anti-Tb therapy in HIV/TB co-infected patients
16 Recruiting Rifampin and Nevirapine Interactions in Young Children
Conditions: Tuberculosis;   HIV
Intervention:
Outcome Measures: Area under time curve (AUC) of nevirapine;   Number of children with grade 3 or 4 liver enzymes elevations compared to baseline, new onset of skin rash, nausea, vomiting or treatment modification due to drug side effects;   Number of children with nevirapine 12-hour post-dose concentration (C12h) < 3000 ng/mL;   Time to HIV-1 RNA suppression below 50 copies/mL and change in CD4 cell count from baseline;   Peak concentration (Cmax) and concentration at 12-hours (C12h) post-dose of nevirapine
17 Recruiting Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Conditions: HIV Infection;   Pulmonary TB
Intervention: Drug: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Outcome Measures: Development of bacteriological failure & Emergence of acquired rifampicin resistance;   Unfavorable responses: clinical failures, recurrences and death due to TB during treatment and follow-up;   TEADR's between the groups;   Incidence of Immune Reconstitution Syndrome among the groups
18 Recruiting Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness
Condition: Latent Tuberculosis Infection
Interventions: Drug: Isoniazid;   Drug: Rifampin
Outcome Measures: Confirmed active TB during 28 months after randomization;   Confirmed active TB in compliant participants;   Probable and confirmed active TB;   Rate of Grade 3 & 4 adverse events;   Comparative cost-effectiveness of regimens;   Occurrence of drug resistance in confirmed cases of active TB
19 Recruiting Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Condition: MRSA Infection
Interventions: Drug: trimethoprim-sulfamethoxazole (TMP-SMX);   Drug: Linezolid;   Drug: Rifampicin
Outcome Measures: Bacteriological and clinical cure;   Treatment costs
20 Recruiting Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
Condition: Cystic Fibrosis
Interventions: Drug: Inhaled Vancomycin;   Drug: Placebo (Sterile Water);   Drug: Rifampin;   Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX);   Drug: Doxycycline;   Drug: Mupirocin Nasal Ointment;   Drug: 4% chlorhexidine gluconate liquid skin cleanser
Outcome Measures: Percentage of patients MRSA free by induced sputum respiratory tract culture;   Change in FEV1% predicted from baseline;   Time to First CF Exacerbation;   Total Number of Pulmonary Exacerbations;   Change if FEV1% Predicted from Screening;   Change in Patient Reported Quality of Life (CFQ-R)(respiratory);   Development of Antibiotic Resistance

These studies may lead to new treatments and are adding insight into Rifampin etiology and treatment.

A major focus of Rifampin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Rifampin